LTX 109

Drug Profile

LTX 109

Alternative Names: LTX-109; Lytixar

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lytix Biopharma
  • Class Antibacterials; Oligopeptides; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Impetigo; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-I/II for Methicillin-resistant Staphylococcus aureus infections in Sweden (Topical)
  • 07 Sep 2015 No recent reports on development identified - Phase-II for Skin and soft tissue infections in Hungary (Topical)
  • 07 Sep 2015 Preclinical trials in Diabetic foot ulcer in Norway (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top